Home » Topics » BioWorld Science

BioWorld Science
RSS

Ensemble Therapeutics divulges IDO-1 inhibitors

June 27, 2018

Fraunhofer-Gesellschaft describes new bacterial glutaminyl cyclase inhibitors

June 27, 2018

Arcus Biosciences, Infinity Pharmaceuticals collaborate on studies of triple combination therapies

June 27, 2018

Apellis initiates phase III trial of APL-2 in PNH

June 27, 2018

Chugai describes OWL-833, an orally active non-peptide GLP-1 receptor agonist

June 27, 2018

In vivo evaluation of PD-L1-targeted PET imaging agent [64Cu]DK222

June 27, 2018

FDA approves Zemdri for cUTI, but issues CRL for bloodstream infections

June 27, 2018

Phase II trial evaluates antimalarial activity of single-dose DSM-265

June 27, 2018

Safety and efficacy of anti-PD-1 antibody SHR-1210 plus apatinib in refractory HCC, GC and EGJC

June 27, 2018

Enteris reports results from final arm of phase IIa trial of Ovarest

June 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.